Last reviewed · How we verify
Insuline glargine
Insulin glargine, marketed by Sanofi, is a long-acting insulin analog that holds a significant position in the diabetes management market. A key strength of insulin glargine is its extended duration of action, which provides stable blood glucose control with once-daily dosing. The primary risk to Sanofi's market position is the expiration of the key composition patent in 2028, which could lead to increased competition from generic and biosimilar products.
At a glance
| Generic name | Insuline glargine |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) (PHASE3)
- Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs (PHASE4)
- Insulin in Total Parenteral Nutrition (PHASE4)
- Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting (PHASE4)
- Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine (PHASE4)
- Insulin Glargine in Type 2 Diabetes Mellitus (PHASE4)
- LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus (PHASE4)
- Glulisine + Lantus in Type I Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insuline glargine CI brief — competitive landscape report
- Insuline glargine updates RSS · CI watch RSS
- Sanofi portfolio CI